Genomic screening is increasing rapidly, but insurance protections globally are outdated. Australia’s new law offers the clearest model yet for safeguarding public trust while supporting population genomics.
Tiller, J. et al.
Final Stakeholder Report of the Australian Genetics and Life Insurance Moratorium: Monitoring the Effectiveness and Response (A-GLIMMER) Project ; https://doi.org/10.26180/23564538 (2023). UK Government & Association of British Insurers.
Code on Genetic Testing and Insurance ; https://go.nature.com/41EvCk5 (2024). Council of Europe.
Convention on Human Rights and Biomedicine (ETS No 164) (Oveido Convention, 1997). Australian Government.
Essentially Yours: The Protection of Human Genetic Information in Australia (ALRC Report 96) (2003). Newson, A.
J., Tiller, J., Keogh, L. A., Otlowski, M.
& Lacaze, P. Public Health Genomics 20 , 247–256 (2017).
Commonwealth of Australia. Parliamentary Joint Committee on Corporations and Financial Services: Life Insurance Industry (2018).
Jones, S. Total Ban on the Use of Adverse Genetic Testing Results in Life Insurance [press release]; https://go.nature.com/41Cfvna (2024).
Public Health Genomics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia Tiller, J. Australia legislates against genetic discrimination in life insurance.
Australia has enacted legislation prohibiting the use of genetic test results by life insurers.
The new law is presented in the source as a contemporary policy response to rapid expansion of genomic screening and perceived inadequacy of existing insurance protections internationally.
The article references the A‑GLIMMER final stakeholder report and multiple prior analyses and policy documents, including national reviews, Parliamentary inquiry findings and comparative codes from the UK and Council of Europe instruments.
These sources underpin the characterization of the Australian measure as a clear model.
The source indicates the change is intended to apply to life insurance underwriting in Australia.
Specifics about which products, risk classes, or exemptions are covered are not reported in the provided content.
The piece frames the legislation as offering the strongest example to date of safeguarding public trust while enabling population genomic initiatives.
It positions the law as addressing a policy gap that risked discouraging participation in genomic screening programs.
The summary material does not report implementation details, enforcement mechanisms, duration, or monitoring plans nor does it provide empirical data on impacts or stakeholder responses beyond citation of the A‑GLIMMER project.